Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCB7858 in healthy subjects
NCT02879877Phase 1Completed
- Sponsor
- UCB
- Start
- Jul 2016
- Primary completion
- Jan 2018
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Zampilimab in chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF) (4 arms), sponsored by UCB. Primary endpoint: Incidence of adverse events following administration of UCB7858. Started Jul 2016; status: completed.
02
Drugs
Zampilimab
03
Conditions
chronic kidney disease (CKD)idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT02879877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02879877.